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Abstract
Glioblastoma multiforme is the most common primary tumor of the central nervous system. The drug temozolomide
(TMZ) prolongs lifespan in many glioblastoma patients. The sensitivity of glioblastoma cells to TMZ is interfered by
many factors, such as the expression of O-6-methylguanine-DNA methyltransferase (MGMT) and activation of AKT
signaling. We have recently identified the interaction between netrin-4 (NTN4) and integrin beta-4 (ITGB4), which
promotes glioblastoma cell proliferation via activating AKT-mTOR signaling pathway. In the current work we have
explored the effect of NTN4/ITGB4 interaction on TMZ induced glioblastoma cell senescence. We report here that
the suppression of either ITGB4 or NTN4 in glioblastoma cell lines significantly enhances cellular senescence. The
sensitivity of GBM cells to TMZ was primarily determined by the expression of MGMT. To omit the effect of MGMT,
we concentrated on the cell lines devoid of expression of MGMT. NTN4 partially inhibited TMZ induced cell
senescence and rescued AKT from dephosphorylation in U251MG cells, a cell line bearing decent levels of ITGB4.
However, addition of exogenous NTN4 displayed no significant effect on TMZ induced senescence rescue or AKT
activation in U87MG cells, which expressed ITGB4 at low levels. Furthermore, overexpression of ITGB4 combined
with exogenous NTN4 significantly attenuated U87MG cell senescence induced by TMZ. These data suggest that
NTN4 protects glioblastoma cells from TMZ induced senescence, probably via rescuing TMZ triggered ITGB4
dependent AKT dephosphorylation. This suggests that interfering the interaction between NTN4 and ITGB4 or
concomitant use of the inhibitors of the AKT pathway may improve the therapeutic efficiency of TMZ.
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Introduction
Netrin-4 is a secreted laminin-related protein, which was
originally observed to guide axons  during neuronal
development [1–3]. Recently, it has been found to be
expressed in many other tissues and tumor types, and to
contribute to the regulation of cell adhesion, migration,
proliferation, and apoptosis [4–8]. In the central nervous
system, NTN4 is strongly expressed by astrocytes [1,2]. In
glioblastoma, high concentrations of NTN4 decrease cell
proliferation in cultured glioblastoma cells. Interestingly, the
expression of NTN4 is down-regulated when compared to
normal brain tissue. However, low concentrations of NTN4
promote glioblastoma cell proliferation via integrin beta-4
signaling. Furthermore, NTN4 is expressed at higher levels in
the white matter-invading glioblastoma cells than in the tumor
cores [9].
Glioblastoma multiforme is the most common primary tumor
of the central nervous system [10,11]. Its median survival
period is less than 15 months after the diagnosis [12]. Although
there are no curative treatments for this fatal disease, the
therapeutic efficacy for temozolomide (TMZ), an orally taken
alkylating agent, has been verified in the treatment of
glioblastoma [13,14]. By combining radiotherapy with TMZ,
patients had significantly longer survival time after diagnosis
[15,16].
The therapeutic function of temozolomide is based on its
capacity to methylate DNA [17,18], which most often causes
cellular cytotoxicity by forming O6-methylguanine adducts.
During DNA replication, O6-methylguanine mispairs with
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thymine [19]. This mismatch subsequently activates endless
futile cycles of the mismatch repair (MMR) system due to the
irreplaceable methylated adduct, leading to single- and double-
strand breaks in DNA. Eventually, these DNA strand breaks
trigger cellular senescence and mitotic arrest in tumors [18,20].
The therapeutic benefit of temozolomide on glioblastoma is
interfered by at least two factors. First, the sensitivity of
glioblastoma cells to TMZ is inhibited by the expression of O-6-
methylguanine-DNA methyltransferase (MGMT) [21,22].
MGMT is a DNA-repair enzyme, which can remove methylated
DNA adducts, thereby abolishing TMZ induced DNA damage
and cell death. Glioblastoma patients with high expression of
MGMT have usually minimal response to temozolomide [23].
Second, the therapeutic efficacy of temozolomide depends on
the activation of AKT, a major regulator of tumorigenesis.
Substantial activation of AKT occurs in a high percentage of
glioblastomas, which is primarily due to the deletion or
inactivation of PTEN [24]. AKT phosphorylation suppresses
temozolomide-induced glioma cell senescence via its various
downstream survival signals [25–27]. Combined treatment of
the AKT inhibitor and temozolomide has additive effects on
glioma and melanoma treatment [28,29].
Among a number of molecular interactions, which construct
an extensive and complicated network to modulate the
activation of AKT [30–32], we found recently an interaction
between NTN4 and ITGB4, which stimulates AKT
phosphorylation [33]. Interestingly, the silencing of ITGB4 can
induce cellular senescence in various cells types [34–36].
Therefore, the NTN4/ITGB4 transduced AKT activation
possibly influences TMZ triggered glioblastoma cell
senescence. We describe here the effects of NTN4-ITGB4
interaction on TMZ induced glioblastoma cell senescence and
clarify the underlying molecular mechanisms.
Materials and Methods
Immunoblotting analysis, transfection of cells, total RNA
extraction, bioinformatics analysis, reverse transcription, and
Real-time Reverse Transcription–PCR were performed as
described [33,37].
Cell Lines and Reagents
U251MG (Health Science Research Resources Bank,
Osaka, Japan), U118MG, T98G, U87MG (American Type
Culture Collection, Rockville, MD) and 293FT cells (Invitrogen
Life Technology, Carlsbad, CA) were cultured according to the
supplier’s instructions.
The following primary antibodies and recombinant protein
were used: anti-ITGB4 from Sigma-Aldrich (St Louis, MO); anti-
AKT, anti–p44/43MAPK (ERK1/2), anti-mammalian target of
rapamycin (mTOR), anti-phosphor AKT (Ser473), anti-
phospho-p44/43MAPK (ERK1/2) (Thr202/Tyr204), and anti-
phospho-mammalian target of rapamycin (mTOR; Ser2448)
from Cell Signaling (Danvers,MA); and anti–β-tubulin from
Santa Cruz Biotechnology (Santa Cruz, CA) and recombinant
NTN4 from R&D Systems (Minneapolis, MN).
TMZ treatment
Temozolomide (Sigma Chemical Co., St. Louis, MO) was
dissolved in DMSO. The cells were treated with TMZ [100 μM]
for 3 h, with the final concentration of DMSO not exceeding
0.1% (v/v). Subsequently, the cells were gently washed twice
with PBS, and then cultured in Dulbecco modified Eagle
medium (DMEM) containing 10% fetal calf serum (FCS) for the
indicated periods of time for further experiments.
Lentiviral Silencing/Overexpression of Gene
Expression
Plasmids expressing shRNAs targeted against the indicated
gene were obtained from The RNAi Consortium through
Biomedicum Helsinki Functional Genomics Unit (FuGU)
(hairpin-pLKO.1 vector). Five different constructs for each gene
were tested. A nontargeting construct was used as control for
nonspecific effects (NT-pLKO.1 vector). Plasmids harboring the
indicated gene were constructed as described [33,37]. pLVX-
puro empty vector was used as a control. To produce
recombinant lentivirus particles, 293FT producer cells were
cotransfected with the packaging/envelope plasmids
(pCMVdr8.74 and pMD2-VSVG; Addgene, Cambridge, MA)
and target plasmids by using the Lipofectamine (Invitrogen)
transfection method. Normal complete culture medium (high-
glucose Dulbecco modified Eagle medium, DMEM) was
changed to the 293FT cells 24 h after transfection.
Subsequently, 48 h later, the viral supernatants were harvested
and filtered through a 0.45-μm filter. The titer of the virus was
investigated. After a 24-hour infection with virus, the
supernatants were replaced with complete medium (DMEM) for
the subsequent assays. For stable shRNA expression, the
infected U251MG cells were subjected to selection with 2 μg/ml
puromycin for 72 h. The efficiency of the transduction was
measured by monitoring the indicated gene expression with Q-
RT-PCR.
Senescence-Associated Beta-Galactosidase Staining
(SA β-gal Staining)
Cells were cultured in 24-well plate at densities of 3000~
5000 cells per well for the indicated times. Subsequently, the
cells were washed once with phosphate buffered saline (PBS,
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4),
and then fixed in PBS containing 0.5% glutaraldehyde at room
temperature for 20 min. After two PBS washes, the cells were
incubated with SA β-gal substrate solution (1 mg/ml X-gal, 40
mM citric acid-sodium phosphate buffer, pH 6.0, containing 5
mM potassium ferricyanide, 5 mM potassium ferrocyanide, 150
mM NaCl, and 2 mM MgCl2) at 37°C in dark for 16-20 h [38].
The reaction was terminated by removing SA β-gal substrate
solution and washing twice with PBS. The cells were stored in
70% glycerol at 4 °C. The cells were finally photographed by
using Axiovert 200 inverted epifluorescence microscope (Carl
Zeiss). The ratio of blue color stained cells was analyzed with
the ImageJ program (National Institutes of Health, Bethesda,
MD).
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Statistical Analysis
All numerical values represent mean ± SE or SD. Statistical
significance was determined with the nonparametric Mann-
Whitney U test.
Results
Silencing of either ITGB4 or NTN4 induces
glioblastoma cell senescence
We have previously analyzed the expression of NTN4 and
ITGB4 genes in the U251MG and U87MG glioblastoma cell
lines. By Q-RT-PCR, we confirmed that both NTN4 and ITGB4
were expressed in all four analyzed glioblastoma cell lines,
namely U251MG, U87MG, U118MG and T98G. Interestingly,
the expression of ITGB4 was much lower in U87MG than in the
other three cell lines (Figure 1A). To understand the effects of
NTN4 and ITGB4 on glioblastoma cell senescence, we
inhibited the expression of these two genes in U251MG cells
by using short hairpin RNAs (shRNAs). The expression levels
of NTN4 and ITGB4 genes were measured by Q-RT-PCR. The
results indicated that three NTN4 and two ITGB4 shRNAs
efficiently reduced the expression in U251MG cells (Figure 1B).
We then detected the number of senescent cells by using
senescence-associated beta-galactosidase assay. We
observed that silencing of either NTN4 or ITGB4 significantly
induced U251MG cell senescence (Figure 1C). Similar results
were obtained by silencing the expression of either NTN4 or
ITGB4 in U118MG, T98G and U87MG cells (Figure 1D).
TMZ induces cell senescence in U251MG and U87MG
cells
We assessed the TMZ sensitivity of four glioblastoma cell
lines by using a cell senescence assay. U87MG cells started to
undergo senescence about 24 h after treatment with TMZ, and
more than 70% of the cells underwent senescence after 72 h.
U251MG cells displayed signs of senescence after 48 h and
more than 70% cells were senescent by 5 days. However,
T98G and U118MG cells showed little or only negligible
sensitivity to TMZ (Figure 2A). We observed next the
expression of MGMT in the cell lines using both Q-RT-PCR
and immunoblotting. We found that MGMT is highly expressed
in the T98G and U118MG cells, but not in U251MG or U87MG
cells (Figure 2B, C). This result is consistent with the previous
reports from other groups [39–42], and suggests that MGMT
provides resistance to TMZ in T98G and U118MG cells. To
investigate whether the expression levels of MGMT and NTN4/
ITGB4 are associated in glioblastoma tissues, we analyzed the
expression levels of primary tumors from The Cancer Genome
Atlas - Glioblastoma multiforme (TCGA-GBM) repository. The
expression of MGMT does not correlate with the expression of
either NTN4 or ITGB4 (Figure 2D). This suggests that the
biological function of either NTN4 or ITGB4 is independent of
the expression of MGMT. Although two MGMT negative cell
lines (U251MG and U87MG) responded to TMZ treatment,
U87MG cells were more sensitive towards TMZ than U251MG
cells. Therefore, we used U87MG and U251MG cells to
investigate the effects of NTN4/ITGB4 interaction on TMZ
induced cell senescence.
NTN4 rescues TMZ induced senescence and AKT
dephosphorylation in U251MG, but not in U87MG cells
Next we explored the effects of exogenous recombinant
NTN4 on TMZ induced senescence. NTN4 significantly
inhibited U251MG cell senescence induced by TMZ (Figure
3A). However, the addition of exogenous NTN4 did not display
any obvious influence on the senescence rate of TMZ -treated
U87MG cells (Figure 3B). U87MG cells expressed ITGB4 at a
much lower level than U251MG cells, both at mRNA (Figure
1A) and protein levels (Figure 3C). Thus, the low expression of
ITGB4 in U87MG cells may impair signal transduction from
NTN4 to AKT. We then analyzed the time scale of the
stimulatory effects of NTN4 on AKT and ERK signaling
pathways in both U87MG and U251MG cell lines after TMZ
treatment. Unexpectedly, the phosphorylation of AKT was
induced immediately after TMZ treatment both in U87MG and
U251MG cells. This phosphorylation effect of AKT lasted for 48
h, and was then severely reduced 72 h later. In contrast, the
phosphorylation of ERK was constantly attenuated in both
U251MG and U87MG cells after the treatment. Accordingly, 72
h after TMZ treatment, the phosphorylation of AKT, ERK and
mTOR, an AKT downstream effector, were significantly
rescued by NTN4 in U251MG, but not in U87MG cells (Figures
4A and 4B). These results indicated that the NTN4-AKT
signaling transduction was at least partially disturbed in
U87MG cells.
NTN4 prevents TMZ induced cellular senescence in
U87MG cell overexpressing ITGB4
We assessed next the role of NTN4 in U87MG cells
overexpressing ITGB4. We generated U87MG cells
overexpressing ITGB4, and confirmed the expression by
immunoblotting (Figure 5A). These cells were then used for
senescence-associated beta-galactosidase assay. Neither in
wild type U87MG cells nor in mock transfected cells did the
addition of exogenous recombinant NTN4 display any
significant effect on TMZ induced cellular senescence.
Interestingly, overexpression of ITGB4 aggravated the
cytotoxicity of TMZ on U87MG cells, but this aggravation was
decreased by endogenous NTN4. Furthermore, NTN4 delayed
the TMZ induced cellular senescence in U87MG cells
overexpressing ITGB4, compared with either wild type or
empty vector control cells (Figures 5B and 5C). Furthermore,
we investigated the effects of NTN4 and TMZ on ITGB4-
silenced U251MG cells. Silencing of ITGB4 increased the
number of U251MG cells undergoing senescence. Although
NTN4 reduced the senescence rate of wild type or non-
targeting control U251MG cells induced by TMZ treatment,
NTN4 did not affect ITGB4-silenced U251MG cells (Figure 5D).
This result indicates that ITGB4 mediates the protective effect
of NTN4 on TMZ treated glioblastoma cells.
Discussion
NTN4 was originally identified as an axon guidance cue.
Besides its role in attracting and/or repelling axons during
neural development, NTN4 is highly expressed in astrocytes,
and it enhances the mitotic ability of neural stem cells through
NTN4 Protects Cells from TMZ Induced Senescence
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Figure 1.  Silencing of the expression of either NTN4 or ITGB4 induces glioblastoma cell senescence.  The expression levels
of NTN4 and ITGB4 were determined in four glioblastoma cell lines by using Q-RT-PCR (A). U251MG cells were infected by
lentivirus harboring shRNAs of target genes and nontargeting control shRNA (NT-shRNA). The silencing efficiencies of each shRNA
were confirmed by Q-RT-PCR (B). Seven days after infection, U251MG cells were fixed and analyzed by the senescence assay.
Silencing of either NTN4 or ITGB4 increased the number of cells undergoing senescence (blue color) in beta-gal staining (C).
Similar results were observed in T98G, U118, and U87MG cells (D). Mean ± SE, n ≥ 3, * p-value < 0.05.
doi: 10.1371/journal.pone.0080363.g001
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Figure 2.  U87MG and U251MG glioblastoma cells are sensitive to TMZ induced senescence.  T98G, U118MG, U251MG and
U87MG cells were treated with TMZ [100μM] for 3 h, and then cultured in medium containing 10% FCS. The cells were
subsequently subjected to a time-course cell senescence assay. The cells were fixed every 24 h and the cell senescence rate was
analyzed by beta-gal assay. U87MG cells were observed to be the most sensitive cell line to TMZ, as the percentage of senescence
increased already 24 h after TMZ treatment. The U251MG cells responded more slowly, and started to undergo senescence about
48 h after the treatment. In contrast, the T98G and U118MG cells were insensitive to TMZ induced senescence (A). The expression
of MGMT in the four glioblastoma cell lines was determined by using both Q-RT-PCR and Western blotting. MGMT was highly
expressed in T98G and U118 cells, but undetectable in U251MG and U87MG cells (B, C).  On the basis of 425 primary GBM
tumors from TCGA, we calculated the Pearson product-moment correlation coefficient. Bioinformatics analysis revealed that the
expression of MGMT does not correlate with the expression of either NTN4 (r value=0.041) or ITGB4 (r value=0.043) (D).  Mean ±
SE, n ≥ 3.
doi: 10.1371/journal.pone.0080363.g002
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Figure 3.  NTN4 partially prevents TMZ induced cell
senescence of U251MG, but not of U87MG cells.  U251MG
and U87MG cells were treated with TMZ [100μM] for 3 h, and
then cultured in medium containing 10% FCS and recombinant
NTN4 protein [100 ng/ml] as indicated. After 4 d (U251MG) or 2
d (U87MG) the cells were subjected to beta-gal staining. NTN4
reduced the senescence rate of TMZ treated U251MG cells
(A), but had no significant effects on U87MG cells (B). Both
U87MG and U251MG cells were cultured to about 50%
confluence, and then lysed for western blotting (WB) analysis.
ITGB4 protein was observed in U251MG cells, but was barely
detectable in U87MG cells. Tubulin was used as a loading
control (C). Mean ± SE, n ≥ 3, ** p-value < 0.01.
doi: 10.1371/journal.pone.0080363.g003
forming a molecular complex with laminin gamma1 chain, and
integrin alpha6beta1 [2]. In glioblastomas NTN4 is expressed
by the tumor cells at the invading edge, and it promotes
glioblastoma cell proliferation via integrin beta-4 mediated AKT-
mTOR signaling [9,33].
We find here that suppression of the expression of either
ITGB4 or NTN4 in different glioblastoma cell lines leads to
cellular senescence, consistently with the results from other
ITGB4 silenced cell types [34–36]. This suggests that the
interaction between NTN4 and ITGB4 can regulate
glioblastoma cell senescence. AKT is an integral part of a
pivotal signaling pathway, which promotes tumor cell
proliferation and protects cells from apoptosis and senescence
via a variety of downstream pathways, such as mammalian
target of rapamycin (mTOR), glycogen synthase kinase 3
(GSK-3) and Forkhead box O (FOXO) [32,43]. Accumulating
experimental evidence indicates that substantial activation of
the PI3K/AKT signaling contributes to tumor cell resistance to
conventional chemotherapy [44–47]. In glioblastomas, AKT
activation can attenuate the therapeutic efficiency of
temozolomide both in vitro and in vivo [25,28,48,49]. Because
NTN4/ITGB4 may together activate AKT, we investigated the
role of this signaling pathway on the temozolomide resistance
of glioblastoma cells. To exclude the interference of MGMT on
TMZ resistance, we selected two MGMT negative glioblastoma
cell lines (U251MG and U87MG) for the current study. We
observed that NTN4 protected TMZ induced cellular
senescence and attenuated TMZ triggered AKT
dephosphorylation in U251MG cells, which express high levels
of ITGB4.
U87MG cells were more sensitive to TMZ treatment than
U251MG cells. This distant outcome in these two cell lines was
due to the lower expression of ITGB4 in U87 cells. This is
possibly due to the expression of wild type p53 gene in U87MG
cell, which enhances TMZ efficiency [50–52].
Unexpectedly, ITGB4 overexpressing U87MG cells were
more sensitive to TMZ than the mock transfected cells.
However, this effect was rescued by exogenous NTN4. One
possible reason is that ITGB4, in the absence of NTN4,
augments oncogenic senescence in U87MG cells, whereas
NTN4/ITGB4 signaling protects the cells from the senescence,
via increased AKT signaling.
Current results suggest that NTN4/ITGB4 stimulated AKT
activation provides glioblastoma cells with the ability of TMZ
resistance. This finding may have clinical significance. Since
the approval of TMZ for patients with newly diagnosed
glioblastoma, the remedy of surgical resection followed by
radiotherapy with concomitant/adjuvant TMZ has become the
new standard of first-line treatment for glioblastoma. However,
the therapeutic efficiency of TMZ still depends on the
expression of MGMT and the activation of AKT signaling
[22,25,27]. Our recent results reveal that glioblastoma tumors
of most patients express low levels of NTN4 and high levels of
ITGB4. This may partially endow glioblastoma cells with the
potential for TMZ sensitivity. However, for patients with
relatively high expression of NTN4 and ITGB4 in glioblastoma
tumors, the prevention of NTN4/ITGB4 interaction or
NTN4 Protects Cells from TMZ Induced Senescence
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Figure 4.  NTN4 partially rescues AKT and ERK phosphorylation in TMZ treated U251MG cells, but not in TMZ treated
U87MG cells.  U251MG and U87MG cells were treated with TMZ [100μM] for 3 h, and then cultured in medium containing 10%
FCS supplemented with recombinant NTN4 protein [100 ng/ml]. Recombinant NTN4 protein was resupplied every 24 h. The cells
were lysed for immunoblotting before (0 h) or after TMZ treatment (3 h), and every 24 h after TMZ treatment (24 h, 48 h, 72 h), total
mTOR, total AKT, total ERK, and tubulin were used as loading control. In both U251MG and U87MG cell lines, the levels of p-AKT
increased immediately after TMZ treatment and were significantly reduced 72 h later, while p-ERK (marked by arrowhead) was
continuously inhibited after TMZ treatment. 72 h after TMZ treatment, NTN4 partially rescued AKT and ERK phosphorylation in
U251MG cells (A), but not in U87MG cells (B).
doi: 10.1371/journal.pone.0080363.g004
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Figure 5.  Overexpression of ITGB4 combined with exogenous NTN4 partially prevents TMZ- induced U87MG cell
senescence .  U87MG cells were transfected to overexpress ITGB4. The expression level of ITGB4 in U87MG was confirmed by
immunoblotting (A). ITGB4 overexpressing U87MG cells were treated with TMZ [100 μM] for 3 h, and then cultured in medium
containing 10% FCS supplemented by recombinant NTN4 protein [100 ng/ml]. After 2 d, the cells were analyzed for senescence by
beta-gal staining. Wild type U87MG and empty vector (Mock) transfected U87MG cells were used as controls. In either wild type
U87MG or mock transfected cells, NTN4 displayed no significant effects on TMZ induced cell senescence. In the absence of
exogenous addition of recombinant NTN4, overexpression of ITGB4 enhanced TMZ induced U87MG cell senescence, whereas in
the presence of recombinant NTN4, the cells overexpressing ITGB4 were partially resistant to TMZ induced cell senescence (B, C).
U251MG cells were infected by lentivirus harboring ITGB4 shRNAs and nontargeting control shRNA (NT-shRNA). Three days after
infection, U251MG cells were treated with TMZ [100μM] for 3 h, and then cultured in medium containing 10% FCS and recombinant
NTN4 protein [100 ng/ml]. Four days later, U251MG cells were fixed and analyzed by beta-gal staining. Silencing of ITGB4
increased the number of U251MG cells undergoing senescence. NTN4 reduced the senescence rate of wild type or non-targeting
control U251MG cells induced by TMZ treatment, but NTN4 did not affect ITGB4-silenced U251MG cells (D). Mean ± SE, n ≥ 3, **p
value < 0.01, * p value < 0.05.
doi: 10.1371/journal.pone.0080363.g005
NTN4 Protects Cells from TMZ Induced Senescence
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concomitant use of the inhibitors of the AKT pathway may
improve the therapeutic benefit of temozolomide.
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